Cooley LLP announced today that it advised Horizon Pharma, Inc. on its acquisition of Dublin-based Vidara Therapeutics International Ltd. for stock and cash valued at approximately $660 million. The resulting company, which will be organized under the laws of Ireland, has a portfolio of four products marketed primarily in the US. The transaction is expected to close by mid-2014.
Horizon is a commercial stage, specialty pharmaceutical company that markets DUEXIS®, VIMOVO® and RAYOS®/LODOTRA®, which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. Horizon’s strategy is to develop, acquire or in-license additional innovative medicines where it can execute a targeted commercial approach to specific physicians, such as primary care physicians, orthopedic surgeons and rheumatologists, while leveraging its commercial strengths and the infrastructure the company has put in place. Vidara is a specialty pharmaceutical company that markets ACTIMMUNE® in the US and maintains operations both in Dublin, Ireland and in the US.
The Cooley team advising Horizon was led by partner and head of the firm’s M&A practice, Barbara Borden, and included partners Kay Chandler, Sean Clayton, Mark Hrenya and Mischi a Marca; special counsel Barry Graynor, Eric Kauffman and Michelle Lara; and associates Wade Andrews, Ben Beerle, Scott Tanner and Matt Robbins. Critical support was provided by partner Jackie Grise (antitrust); partner Natasha Leskovsek (life sciences); of counsel John Steines and associate Michael Baker (tax).
Related Posts:
- Cooley Advises Insys Therapeutics on Its IPO
- Cooley Advises Jazz Pharmaceuticals in $314.4 Million Offering
- Cooley Advises Depomed in its $240 Million Diabetes Drug Sale to PDL BioPharma
- Isis Pharmaceuticals Completes Rule 144A Offering of $500 Million of Convertible Senior Notes
- Cooley Advises Jazz Pharmaceuticals plc on Rule 144A Offering of $575 Million of Exchangeable Senior Notes
